GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technolo

[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has r

Peer-reviewed clinical results and strong patient preference support growing use across neurology pr

GUILFORD, Conn.--(BUSINESS WIRE)--Peer-reviewed NEURO PMR results and 3,000+ office brain MRI scans

[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has r

This advancement is Hyperfine’s second FDA-cleared software package since the launch of its next-gen

GUILFORD, Conn.--(BUSINESS WIRE)--FDA-cleared Optive AI software enhances Swoop system image quality

B. Riley Securities analyst Yuan Zhi reiterates Hyperfine (NASDAQ:HYPR) with a Buy and lowers the

Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine NASDAQ: HYPR reported second-quarter revenue of $3.9 million, up approximately 45% from a

Hyperfine (NASDAQ:HYPR) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000

Hyperfine (NASDAQ:HYPR) reported quarterly losses of $(0.09) per share which met the analyst consens

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technolo

GUILFORD, Conn.--(BUSINESS WIRE)--Multiple peer-reviewed publications in Journal of Neurosurgery and

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine will report Q2 2026 financial results Thur., Aug. 6, 202

This marks a significant milestone in the company’s global expansion of its most advanced portable M

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine initiates the launch of the next-gen Swoop® system in Eu

GUILFORD, Conn.--(BUSINESS WIRE)--Leading neurosurgeons will help guide the role of the Swoop® syste

[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has r

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces Swoop® system scan volume milestones at key ho

Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Tran

[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has r

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine is expected to join broad-market Russell 3000® Index & s

GUILFORD, Conn.--(BUSINESS WIRE)--PRIME study results show bedside portable MRI cut order-to-scan ti

Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript

Hyperfine NASDAQ: HYPR reported a sharp year-over-year increase in first-quarter revenue and reitera

HYPERFINE, INC.Up to 1,083,335 Shares of Class A Common StockThis prospectus relates to the resale f

Hyperfine (NASDAQ:HYPR) reported quarterly losses of $(0.09) per share which met the analyst consens

Top analysts change outlook on Hyperfine Inc, Legence, and Aktis Oncology with Buy/Outperform rating

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain

BTIG analyst Marie Thibault initiates coverage on Hyperfine (NASDAQ:HYPR) with a Buy rating and a

This milestone unlocks Hyperfine's most significant technology innovations to date for clinician

Lake Street analyst Frank Takkinen maintains Hyperfine (NASDAQ:HYPR) with a Buy and raises the pr

Hyperfine (NASDAQ:HYPR) reported quarterly losses of $(0.06) per share which beat the analyst consen

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brai

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brai

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain

Expansion of initiatives with AI-powered portable MRI will enable evaluation of childhood brain deve

Hyperfine (NASDAQ:HYPR) lowers FY2025 sales outlook from $14.179 million-$15.468 million to $13.000

Hyperfine (NASDAQ:HYPR) reported quarterly losses of $(0.14) per share which missed the analyst cons

With several patients already enrolled in the study, PRISM PMR is designed to evaluate the Swoop® sy